A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants with Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non interventional Cohort

Trial Identifier: D8380C00001
Sponsor: AstraZeneca
Collaborator:
Parexel International LLC
Start Date: June 2025
Primary Completion Date: April 2026
Study Completion Date: April 2026
Condition: Chronic Kidney Diseases

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, CA Glendale, CA, US, 91206
US, IL Chicago, IL, US, 60643
US, MI Ann Arbor, MI, US, 48109
US, MN Saint Paul, MN, US, 55114
US, TX San Antonio, TX, US, 78215